DCTH Strangle Strategy
DCTH (Delcath Systems, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH (Delcath Systems, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $400.8M, a trailing P/E of 745.47, a beta of 0.54 versus the broader market, a 52-week range of 8.12-18.23, average daily share volume of 449K, a public-listing history dating back to 2018, approximately 96 full-time employees. These structural characteristics shape how DCTH stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.54 indicates DCTH has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 745.47 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on DCTH?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current DCTH snapshot
As of May 15, 2026, spot at $11.11, ATM IV 65.80%, IV rank 10.33%, expected move 18.86%. The strangle on DCTH below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on DCTH specifically: DCTH IV at 65.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a DCTH strangle, with a market-implied 1-standard-deviation move of approximately 18.86% (roughly $2.10 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DCTH expiries trade a higher absolute premium for lower per-day decay. Position sizing on DCTH should anchor to the underlying notional of $11.11 per share and to the trader's directional view on DCTH stock.
DCTH strangle setup
The DCTH strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DCTH near $11.11, the first option leg uses a $11.67 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DCTH chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DCTH shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $11.67 | N/A |
| Buy 1 | Put | $10.55 | N/A |
DCTH strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
DCTH strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on DCTH. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on DCTH
Strangles on DCTH are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DCTH chain.
DCTH thesis for this strangle
The market-implied 1-standard-deviation range for DCTH extends from approximately $9.01 on the downside to $13.21 on the upside. A DCTH long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current DCTH IV rank near 10.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DCTH at 65.80%. As a Healthcare name, DCTH options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DCTH-specific events.
DCTH strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DCTH positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DCTH alongside the broader basket even when DCTH-specific fundamentals are unchanged. Always rebuild the position from current DCTH chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on DCTH?
- A strangle on DCTH is the strangle strategy applied to DCTH (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With DCTH stock trading near $11.11, the strikes shown on this page are snapped to the nearest listed DCTH chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DCTH strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the DCTH strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 65.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DCTH strangle?
- The breakeven for the DCTH strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DCTH market-implied 1-standard-deviation expected move is approximately 18.86%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on DCTH?
- Strangles on DCTH are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DCTH chain.
- How does current DCTH implied volatility affect this strangle?
- DCTH ATM IV is at 65.80% with IV rank near 10.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.